Loading clinical trials...
Loading clinical trials...
A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis
Conditions
Interventions
NeuroVax
IFA Incomplete Freund's Adjuvant
Locations
1
United States
CRO
San Diego, California, United States
Start Date
December 31, 2020
Primary Completion Date
November 9, 2024
Completion Date
November 9, 2024
Last Updated
March 31, 2020
NCT06276634
NCT07225504
NCT06809192
NCT05359653
NCT07426991
NCT07376772
Lead Sponsor
Immune Response BioPharma, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions